Efficacy of zofenopril alone or in combination with hydrochlorothiazide in patients with kidney dysfunction
Omboni S., Borghi C.
Current Clinical Pharmacology
Vol.14, Issue1, P. 5-15
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.2174/1574884713666181025145404
Аннотация:
Hypertension and kidney disease often coexist, further increasing the risk of future cardiovascular events. Treatment of hypertensive adults with an angiotensin converting enzyme inhibitor in case of concomitant kidney disease may slow disease progression. The third-generation liphophilic angiotensin converting enzyme inhibitor zofenopril, administered alone or combined with a thiazide diuretic, has proved to be effective in lowering blood pressure in hypertensive patients and to reduce the risk of fatal and non-fatal events in post-acute myocardial infarction and heart failure. In almost three-hundred hypertensive patients with kidney impairment zofenopril administered for 12 weeks showed a similar blood pressure-lowering effect irrespective of the stage of the disease, with larger effects in combination with a thiazide diuretic, particularly in patients with slightly or moderately impaired kidney function. In animal models, zofenopril produced a significant and long-lasting inhibitio
Ключевые слова:
Angiotensin-converting enzyme inhibitors; Arterial hypertension; Chronic kidney disease; Hydrochlorothiazide; Kidney dysfunction; Zofenopril
amlodipine; atenolol; candesartan; enalapril; hydrochlorothiazide; irbesartan; lisinopril; losartan; nifedipine; placebo; propranolol; ramipril; zofenopril; captopril; dipeptidyl carboxypeptidase inhibitor; diuretic agent; hydrochlorothiazide; zofenopril; acute heart infarction; Article; creatinine clearance; diastolic blood pressure; drug accumulation; drug blood level; drug dose increase; drug efficacy; drug elimination; drug excretion; end stage renal disease; essential hypertension; glomerulus filtration rate; heart failure; hemodialysis; human; hypertension; kidney dysfunction; microalbuminuria; mild renal impairment; moderate renal impairment; monotherapy; nonhuman; priority journal; renal ischemia reperfusion injury; renal protection; severe renal impairment; single drug dose; systolic blood pressure; animal; combination drug therapy; kidney disease; pathophysiology; treatment outcome; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diuretics; Drug Therapy, Combina
Язык текста: Английский
ISSN: 1574-8847
Omboni S. Stefano 1963-
Borghi C.
Омбони С. Стефано 1963-
Боргхи C.
Efficacy of zofenopril alone or in combination with hydrochlorothiazide in patients with kidney dysfunction
Текст визуальный непосредственный
Current Clinical Pharmacology
Vol.14, Issue1 P. 5-15
2019
Статья
Angiotensin-converting enzyme inhibitors Arterial hypertension Chronic kidney disease Hydrochlorothiazide Kidney dysfunction Zofenopril
amlodipine atenolol candesartan enalapril hydrochlorothiazide irbesartan lisinopril losartan nifedipine placebo propranolol ramipril zofenopril captopril dipeptidyl carboxypeptidase inhibitor diuretic agent hydrochlorothiazide zofenopril acute heart infarction Article creatinine clearance diastolic blood pressure drug accumulation drug blood level drug dose increase drug efficacy drug elimination drug excretion end stage renal disease essential hypertension glomerulus filtration rate heart failure hemodialysis human hypertension kidney dysfunction microalbuminuria mild renal impairment moderate renal impairment monotherapy nonhuman priority journal renal ischemia reperfusion injury renal protection severe renal impairment single drug dose systolic blood pressure animal combination drug therapy kidney disease pathophysiology treatment outcome Angiotensin-Converting Enzyme Inhibitors Animals Captopril Diuretics Drug Therapy, Combina
Hypertension and kidney disease often coexist, further increasing the risk of future cardiovascular events. Treatment of hypertensive adults with an angiotensin converting enzyme inhibitor in case of concomitant kidney disease may slow disease progression. The third-generation liphophilic angiotensin converting enzyme inhibitor zofenopril, administered alone or combined with a thiazide diuretic, has proved to be effective in lowering blood pressure in hypertensive patients and to reduce the risk of fatal and non-fatal events in post-acute myocardial infarction and heart failure. In almost three-hundred hypertensive patients with kidney impairment zofenopril administered for 12 weeks showed a similar blood pressure-lowering effect irrespective of the stage of the disease, with larger effects in combination with a thiazide diuretic, particularly in patients with slightly or moderately impaired kidney function. In animal models, zofenopril produced a significant and long-lasting inhibitio